Stephen Saad's Aspen Pharmacare predicts double-digit growth despite tough first half
Billionaires Africa | 05.03.2026 17:04
South Africa's largest pharmaceutical company on Tuesday reported a 21% decline in normalised headline earnings for the six months ended Dec. 31, dragged down by one-off restructuring costs at its sterile manufacturing facilities. But CEO Stephen Saad told investors the pain is temporary, and that double-digit profit growth is coming before the financial year is out.
